Thus, the attenuation of hepatic lipid deposition along with upregulation of mRNA abundance of Srebf1, Fasn, Acaca and downregulation of Cpt1 and Apoa1 in response to supplementation with CFH03 underscored its potential for improving NAFLD. The gene discussed is APOA1; the disease is metabolic dysfunction-associated steatotic liver disease.